Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Notable Labs (NTBL)
NASDAQ:NTBL
Notable Labs (NTBL) Stock Price & Analysis
723 Followers
NTBL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.83 - $11.23
Previous Close$0.98
Volume39.54K
Average Volume (3M)93.70K
Market Cap
$8.75M
Enterprise Value-$1.03M
Total Cash (Recent Filing)$11.82M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)-4.6
Beta1.23
Next Earnings
May 16, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding9,018,261
10 Day Avg. Volume79,219
30 Day Avg. Volume93,696
Standard Deviation0.23
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)28.22
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.32
Enterprise Value/Gross Profit-9.10
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$8.00Price Target Upside720.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Notable Labs News
PremiumCompany Announcements
Notable Labs Shares Strategic Insights in Business Overview
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNotable's lead program, volasertib, has shown clinical activity across liquid and solid tumors in phase I/II/III studies.
Financial StabilityManagement expects current cash is sufficient to fund planned operations into the fourth quarter of the following year.
Operational EfficiencyNotable Labs will kick off the volasertib AML trial soon, moving directly into the Ph2 trial portion.
Bears Say
Clinical Trial ResultsThe lack of efficacy in all patients treated with Fosciclopirox raises questions about the predictive capabilities of the PPMP platform.
Drug EfficacyFosciclopirox did not produce any responses in nine evaluable AML patients, which darkens the outlook for the drug in AML treatment.
Financial Model AdjustmentAnalysts have conservatively removed Fosciclopirox from their model, leading to a reduced price target for NTBL's stock.
---
Ownership Overview
70.02% Insiders
0.01% Mutual Funds
2.27% Other Institutional Investors
27.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NTBL FAQ
What was Notable Labs’s price range in the past 12 months?
Notable Labs lowest stock price was $0.83 and its highest was $11.23 in the past 12 months.
What is Notable Labs’s market cap?
Currently, no data Available
When is Notable Labs’s upcoming earnings report date?
Notable Labs’s upcoming earnings report date is May 16, 2024 which is in 7 days.
How were Notable Labs’s earnings last quarter?
Notable Labs released its earnings results on Apr 12, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.39 by -$0.47.
Is Notable Labs overvalued?
According to Wall Street analysts Notable Labs’s price is currently Undervalued.
Does Notable Labs pay dividends?
Notable Labs does not currently pay dividends.
What is Notable Labs’s EPS estimate?
Notable Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Notable Labs have?
Notable Labs has 9,018,261 shares outstanding.
What happened to Notable Labs’s price movement after its last earnings report?
Notable Labs reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.39. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of Notable Labs?
Among the largest hedge funds holding Notable Labs’s share is ARK Investment Management LLC. It holds Notable Labs’s shares valued at N/A.
---
Notable Labs Stock Smart Score
Company Description
Notable Labs
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
---
NTBL Stock 12 Month Forecast
Average Price Target
$8.00
▲(720.51% Upside)
Technical Analysis
Best Analysts Covering NTBL
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-42.65%
reiterated a buy rating 24 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.65% per trade.
---